These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 3113225)

  • 21. Recombinant single-chain urokinase-type plasminogen activator during acute myocardial infarction.
    Diefenbach C; Erbel R; Pop T; Mathey D; Schofer J; Hamm C; Ostermann H; Schmitz-Hübner U; Bleifeld W; Meyer J
    Am J Cardiol; 1988 May; 61(13):966-70. PubMed ID: 2452563
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Initial experiences with pro-urokinase in acute myocardial infarct].
    Schanzenbächer P; Huber J; Keller F; Kochsiek K
    Z Kardiol; 1987 Sep; 76(9):570-5. PubMed ID: 3122430
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased thrombin levels during thrombolytic therapy in acute myocardial infarction. Relevance for the success of therapy.
    Gulba DC; Barthels M; Westhoff-Bleck M; Jost S; Rafflenbeul W; Daniel WG; Hecker H; Lichtlen PR
    Circulation; 1991 Mar; 83(3):937-44. PubMed ID: 1900225
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hyperacute stroke therapy with tissue plasminogen activator.
    Alberts MJ
    Am J Cardiol; 1997 Aug; 80(4C):29D-34D; discussion 35D-39D. PubMed ID: 9284041
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potentiation of the thrombolytic efficacy of single-chain urokinase (Pro-urokinase) by heparin.
    Gulba DC; Fischer K; Reil GH; Daniel WG; Lichtlen PR
    Thromb Haemost; 1988 Oct; 60(2):350-1. PubMed ID: 3146150
    [No Abstract]   [Full Text] [Related]  

  • 26. [Acute portal vein thrombosis treated with locoregional fibrinolysis: a case report].
    Morelli Coppola G; Niola R; Regine R; Frongillo A; Nasti G; Maglione F
    Radiol Med; 2001; 102(5-6):412-5. PubMed ID: 11779996
    [No Abstract]   [Full Text] [Related]  

  • 27. [Effects of intravenous administration of nasaruplase, a plasminogen pro-activator, on left ventricular function and systemic hemodynamics in a canine model of acute myocardial infarction].
    Kido H; Kubo Y; Inoue S; Hayashi K; Narita Y; Uchida T; Watanabe M
    Nihon Yakurigaku Zasshi; 1993 Feb; 101(2):79-91. PubMed ID: 8454229
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evolving concepts in the treatment of acute myocardial infarction.
    Lange RA; Hillis LD
    Am J Med Sci; 1988 Aug; 296(2):143-52. PubMed ID: 3041833
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How should intravenous thrombolytic agents for acute myocardial infarction be selected?
    Topol EJ
    Cardiovasc Clin; 1990; 21(1):57-75; discussion 76-8. PubMed ID: 2143103
    [No Abstract]   [Full Text] [Related]  

  • 30. Criteria for use of regional urokinase infusion for deep vein thrombosis.
    Kaul AF; Tomera JF
    Am J Health Syst Pharm; 1997 Sep; 54(17):2002-3. PubMed ID: 9290901
    [No Abstract]   [Full Text] [Related]  

  • 31. [Thrombolytic therapy of ischemic heart disease].
    Kanmatsuse K; Nagao K; Kikushima K; Shioiri K
    Nihon Naika Gakkai Zasshi; 1997 Sep; 86(9):1625-8. PubMed ID: 9410972
    [No Abstract]   [Full Text] [Related]  

  • 32. Coronary thrombolysis with human single-chain, urokinase-type plasminogen activator (pro-urokinase) in patients with acute myocardial infarction.
    Van de Werf F; Nobuhara M; Collen D
    Ann Intern Med; 1986 Mar; 104(3):345-8. PubMed ID: 3080936
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Acyl enzymes and pro-urokinase: promising new thrombolytic agents].
    Samama M; Horellou MH; Nguyen G; Conard J
    Haemostasis; 1986; 16 Suppl 4():35-9. PubMed ID: 3095199
    [No Abstract]   [Full Text] [Related]  

  • 34. Acute infarction, intracoronary thrombolysis, and primary PTCA in pregnancy.
    Webber MD; Halligan RE; Schumacher JA
    Cathet Cardiovasc Diagn; 1997 Sep; 42(1):38-43. PubMed ID: 9286538
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful local arterial urokinase infusion to reverse late postoperative venous thrombosis of a renal graft.
    Bedani PL; Galeotti R; Mugnani G; Risichella IS; Rizzioli E; Verzola A; Borgatti L; Sala S; La Torre C; Stabellini G; Gilli P
    Nephrol Dial Transplant; 1999 Sep; 14(9):2225-7. PubMed ID: 10489239
    [No Abstract]   [Full Text] [Related]  

  • 36. [New thrombolytic agents in myocardial infarction].
    Charbonnier B; Lang M; Brochier M
    Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Back to the future: so what will fibrinolytic therapy offer your patients with myocardial infarction?
    Mitchell JR
    Br Med J (Clin Res Ed); 1986 Apr; 292(6526):973-8. PubMed ID: 3083976
    [No Abstract]   [Full Text] [Related]  

  • 38. Efficacy of intravenous prourokinase and a combination of prourokinase and urokinase in acute myocardial infarction.
    Bode C; Schoenermark S; Schuler G; Zimmermann R; Schwarz F; Kuebler W
    Am J Cardiol; 1988 May; 61(13):971-4. PubMed ID: 2452564
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thrombolytic agents for acute evolving myocardial infarction: comparative effects.
    Sherry S
    Ration Drug Ther; 1987 Jan; 21(1):1-9. PubMed ID: 3112866
    [No Abstract]   [Full Text] [Related]  

  • 40. New thrombolytic drugs in acute myocardial infarction: theoretical and practical considerations.
    Verstraete M
    Circulation; 1987 Aug; 76(2 Pt 2):II31-8. PubMed ID: 3111745
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.